Goldman Sachs has begun coverage of Sanofi, listed on NASDAQ as SNY, with a neutral rating. The bank acknowledged that the French pharmaceutical company is “emerging as a pipeline story” but emphasized the need for additional data from its drug candidates before adopting a more favorable stance. Goldman Sachs has set a price target of $65 for Sanofi’s stock, representing an approximate 13% potential increase.
Goldman Sachs Rates Sanofi Neutral, Citing Need for Pipeline Successes
Related stories
Finance News
Top 2025 MLB Starting Pitcher Salaries: Who Earns the Most?
The 2025 Major League Baseball season has commenced, highlighting...
Business
China Prepares for Impact as New Trump Tariffs Approach
The White House Watch newsletter offers insight into the...
Latest News
U.S. Benefits from Implementing Reciprocal Tariffs
Reciprocal tariffs are set to be implemented soon, leading...
Technology
Watch Scotland vs. Greece 2025: Free UEFA Nations League Livestream
The UEFA Nations League match between Scotland and Greece...

DMN8 Partnershttps://salvonow.com/
DMN8 Partners utilizes a strategy of Cross Channel marketing including local search engine optimization, PPC, messaging and hyper-targeted audiences allow our clients to experience results and ROI that fuel growth and expansion in their operations. There are a lot of digital marketing options across the country but partnering with an agency that understands multiple touches on multiple platforms allows your company’s message to be seen at the perfect time, on the perfect platform, by your perfect prospect. DMN8 Partners has had years of experience growing businesses. Start growing your business today and begin DOMINATE-ing your market.